Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
Last trade$5.74
Day change+$0.105 (+1.87%)
Day range$5.48 – $5.76
Volume535,386
Market cap$736M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$736.31M
Price / earnings
—
Price / book
2.29×
Price / sales
3.55×
EV / sales
3.22×
EV / EBITDA
-18.6×
Profitability
Earnings per share
-$0.62
Return on assets
-18.2%
Return on equity
-25.27%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.46×
Quick ratio
3.84×
Cash ratio
0.79×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.48M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CTKB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$53.23M
$48.14M
$44.14M
$62.14M
$52.29M
$45.6M
$41.46M
$57.48M
Cost of revenue
$22.02M
$19.8M
$22.88M
$29.26M
$24.74M
$21.74M
$21.3M
$23.82M
Gross profit
$31.21M
$28.34M
$21.25M
$32.89M
$27.55M
$23.87M
$20.16M
$33.65M
Selling, general and administrative
$30.27M
$30M
$30.11M
$29.52M
$27.79M
$25.67M
$25.41M
$20.94M
Research and development
$9.36M
$9.74M
$9.6M
$8.96M
$8.96M
$8.83M
$9.73M
$9.72M
Total operating expenses
$39.63M
$39.74M
$39.72M
$38.48M
$36.74M
$34.49M
$35.13M
$30.67M
Operating income
-$8.42M
-$11.4M
-$18.46M
-$5.59M
-$9.19M
-$10.62M
-$14.98M
$2.99M
Interest expense
-$260K
-$281K
-$262K
$725K
-$494K
-$414K
-$291K
$5.93M
Income before taxes
-$6.91M
-$11.64M
-$17.37M
-$4.03M
-$7.77M
-$6.78M
-$11.27M
$10.32M
Income taxes
-$811K
$515K
$1.49M
$40.05M
-$2.29M
-$1.19M
$136K
$680K
Net income
-$6.1M
-$12.16M
-$18.87M
-$44.08M
-$5.48M
-$5.58M
-$11.4M
$9.64M
Net income attributable to common shareholders
-$6.1M
-$12.16M
-$18.87M
-$44.08M
-$5.48M
-$5.58M
-$11.4M
$9.64M
EBITDA
-$6.31M
-$9.39M
-$16.6M
-$3.7M
-$7.27M
-$8.73M
-$13.1M
$4.84M
Basic earnings per share
-$0.05
-$0.09
-$0.15
-$0.34
-$0.04
-$0.04
-$0.09
$0.07
Diluted earnings per share
-$0.05
-$0.09
-$0.15
-$0.34
-$0.04
-$0.04
-$0.09
$0.08
Recent news
Company coverage with links to the original publishers.
Cytek Biosciences announced that its Cytek Aurora Evo system has been named Drug Discovery Innovation of the Year in the 2026 BioTech Breakthrough Awards. The system features enhanced throughput, automation, and data consistency capabilities, with approximately 40% faster acquisition time for plate-based workflows and automated startup/shutdown functions to improve laboratory efficiency.
Cytek Biosciences is expected to report a year-over-year earnings decline with higher revenues when it releases Q3 2026 results on November 4. The company is projected to post a quarterly loss of $0.08 per share with revenues of $52.9 million (up 1.2% YoY). With an Earnings ESP of 0% and Zacks Rank #3, the stock is not considered a compelling earnings-beat candidate. The company has failed to beat consensus EPS estimates in the last four quarters.
Cytek Biosciences unveiled its new 7-laser Cytek Borealis full spectrum flow cytometer featuring Deep Ultraviolet and Infrared capabilities with 120 detectors, enabling high-resolution 60-color panels. The company also announced automation-ready configurations for the Cytek Aurora Evo system designed to integrate with robotic plate handling and third-party scheduling platforms, targeting biopharma and CRO organizations.
Cytek Biosciences marks the one-year anniversary of its 8,500-square-foot Singapore facility, which has enhanced manufacturing capacity, regional service capabilities, and supply chain resilience. The facility serves as a strategic hub for Asia-Pacific operations and supports the company's growth in cell analysis solutions driven by increasing global demand in immunology, immuno-oncology, and cancer research.
Cytek Biosciences announced preliminary Q4 2025 revenue of approximately $62 million, representing 8% year-over-year growth and 19% sequential growth. Full year 2025 revenue is expected to be approximately $201 million. The company highlighted strong growth in Services, Reagents, and Asia Pacific instrument revenue, along with improved instrument sales in the US and EMEA regions, particularly a return to positive growth in EMEA.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.